| 0.5342 -0.295 (-35.56%) | 06-01 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.98 |
1-year : | 1.2 |
| Resists | First : | 0.84 |
Second : | 1.02 |
| Pivot price | 0.86 |
|||
| Supports | First : | 0.53 |
Second : | 0.44 |
| MAs | MA(5) : | 0.81 |
MA(20) : | 0.88 |
| MA(100) : | 1.16 |
MA(250) : | 2.2 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 24.7 |
D(3) : | 40 |
| RSI | RSI(14): 25.1 |
|||
| 52-week | High : | 7.19 | Low : | 0.53 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ JSPR ] has closed below the lower bollinger band by 34.1%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ JSPR ] is to continue within current trading range. Bollinger Bands are 0.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.86 - 0.87 | 0.87 - 0.87 |
| Low: | 0.52 - 0.53 | 0.53 - 0.53 |
| Close: | 0.53 - 0.53 | 0.53 - 0.54 |
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of conditioning agents and stem cell engineering to allow expanded use of stem cell transplantation and ex vivo gene therapy, a technique in which genetic manipulation of cells is performed outside the body prior to transplantation. The company's lead product candidate is JSP191, which is in clinical development as a conditioning antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is based in Redwood City, California.
Mon, 01 Jun 2026
Jasper Therapeutics explores strategic alternatives By Investing.com - Investing.com Australia
Mon, 01 Jun 2026
Jasper Therapeutics begins strategic review to maximize shareholder value - TradingView
Mon, 01 Jun 2026
Jasper Therapeutics (NASDAQ: JSPR) weighs sale, merger or wind-down options - Stock Titan
Mon, 01 Jun 2026
Biotech Jasper Therapeutics weighs options from asset sale to wind-down - Stock Titan
Mon, 01 Jun 2026
Jasper Therapeutics Announces Exploration of Strategic Alternatives to Maximize Shareholder Value - GlobeNewswire
Thu, 14 May 2026
Jasper Therapeutics (NASDAQ: JSPR) cuts Q1 2026 loss but flags funding risk - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 28 (M) |
| Shares Float | 22 (M) |
| Held by Insiders | 1.1 (%) |
| Held by Institutions | 60.5 (%) |
| Shares Short | 2,490 (K) |
| Shares Short P.Month | 2,730 (K) |
| EPS | -2.58 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.11 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -112.3 % |
| Return on Equity (ttm) | -244.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.5 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -69 (M) |
| Levered Free Cash Flow | -41 (M) |
| PE Ratio | -0.21 |
| PEG Ratio | 0 |
| Price to Book value | 4.45 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.22 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|